Sign in or create an account to add this stock to your watchlist.
About Rocket Pharmaceuticals (NASDAQ:RCKT)
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development. The company has collaboration agreements with Lund University, Sweden; and Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas. The company is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RCKT
CUSIPN/A
Phone646-440-9100
Debt
Debt-to-Equity Ratio0.23
Current Ratio23.31
Quick Ratio23.31
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.02 per share
Price / Book2.86
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-29,490,000.00
Net MarginsN/A
Return on Equity-51.66%
Return on Assets-31.55%
Miscellaneous
Employees20
Outstanding Shares39,470,000
Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions
What is Rocket Pharmaceuticals' stock symbol?
Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."
How were Rocket Pharmaceuticals' earnings last quarter?
Rocket Pharmaceuticals (NASDAQ:RCKT) issued its quarterly earnings results on Friday, May, 11th. The biotechnology company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.14. View Rocket Pharmaceuticals' Earnings History.
When is Rocket Pharmaceuticals' next earnings date?
What price target have analysts set for RCKT?
4 brokerages have issued 12-month price objectives for Rocket Pharmaceuticals' stock. Their predictions range from $2.00 to $27.00. On average, they anticipate Rocket Pharmaceuticals' share price to reach $10.6667 in the next twelve months. View Analyst Ratings for Rocket Pharmaceuticals.
Who are some of Rocket Pharmaceuticals' key competitors?
Some companies that are related to Rocket Pharmaceuticals include Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO), Heron Therapeutics (HRTX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), OPKO Health (OPK) and Evotec A.G. (EVTCY).
Who are Rocket Pharmaceuticals' key executives?
Rocket Pharmaceuticals' management team includes the folowing people:
- Mr. Gaurav Shah M.D., Chief Exec. Officer
- Mr. Brian Batchelder, Head of Fin. and VP
- Ms. Kinnari Patel PharmD, MBA, Head of Regulatory, Pharmacovigilance & Compliance and VP
- Mr. Jonathan Schwartz M.D., Chief Medical Officer and Head of Clinical Devel.
- Mr. Naveen Yalamanchi, Chief Bus. Officer
Has Rocket Pharmaceuticals been receiving favorable news coverage?
News coverage about RCKT stock has trended somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Rocket Pharmaceuticals earned a coverage optimism score of 0.09 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.42 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Rocket Pharmaceuticals' major shareholders?
Rocket Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Tang Capital Management LLC (7.51%), Citadel Advisors LLC (1.06%), Eventide Asset Management LLC (1.00%), Acuta Capital Partners LLC (0.89%), Sphera Funds Management LTD. (0.77%) and Artal Group S.A. (0.63%). View Institutional Ownership Trends for Rocket Pharmaceuticals.
Which major investors are buying Rocket Pharmaceuticals stock?
RCKT stock was bought by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Citadel Advisors LLC, Eventide Asset Management LLC, Acuta Capital Partners LLC, Sphera Funds Management LTD., Artal Group S.A., Highbridge Capital Management LLC and Iguana Healthcare Management LLC. View Insider Buying and Selling for Rocket Pharmaceuticals.
How do I buy shares of Rocket Pharmaceuticals?
Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rocket Pharmaceuticals' stock price today?
One share of RCKT stock can currently be purchased for approximately $20.07.
How big of a company is Rocket Pharmaceuticals?
Rocket Pharmaceuticals has a market capitalization of $785.51 million. Rocket Pharmaceuticals employs 20 workers across the globe.
How can I contact Rocket Pharmaceuticals?
Rocket Pharmaceuticals' mailing address is 430 EAST 29TH STREET SUITE 1040, NEW YORK NY, 10016. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected]
MarketBeat Community Rating for Rocket Pharmaceuticals (RCKT)
MarketBeat's community ratings are surveys of what our community members think about Rocket Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCKT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCKT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Rocket Pharmaceuticals in the last 12 months. Their average twelve-month price target is $10.6667, suggesting that the stock has a possible downside of 46.85%. The high price target for RCKT is $27.00 and the low price target for RCKT is $2.00. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Hold | Hold |
| Consensus Rating Score: | 2.50 | 2.50 | 2.33 | 2.25 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $10.6667 | $10.6667 | $10.6667 | $4.50 |
| Price Target Upside: | 46.85% downside | 40.64% downside | 41.78% downside | 373.68% upside |
Rocket Pharmaceuticals (NASDAQ:RCKT) Consensus Price Target History
Rocket Pharmaceuticals (NASDAQ:RCKT) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Rocket Pharmaceuticals (NASDAQ:RCKT) Earnings History and Estimates Chart
Rocket Pharmaceuticals (NASDAQ RCKT) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2018 | | | | | | | | |
| 5/11/2018 | Q1 2018 | ($0.28) | ($0.42) | | | View | N/A |  |
| 8/3/2017 | Q2 2017 | ($0.47) | ($0.24) | | | View | N/A | |
| 5/10/2017 | Q1 2017 | ($0.3930) | ($0.40) | | | View | N/A | |
| 3/16/2017 | Q4 2016 | ($0.4320) | ($0.4810) | | | View | N/A | |
| 11/9/2016 | Q3 2016 | ($0.45) | ($0.41) | | | View | N/A | |
| 8/10/2016 | Q2 | ($0.40) | ($0.33) | | | View | N/A | |
| 5/11/2016 | Q1 | ($0.22) | ($0.38) | | | View | N/A | |
| 3/23/2016 | Q4 | ($0.37) | ($0.13) | | | View | N/A | |
| 11/12/2015 | Q3 2015 | ($1.84) | ($1.00) | | | View | N/A | |
| 8/6/2015 | Q2 2015 | ($0.29) | ($0.26) | | | View | N/A | |
| 5/15/2015 | Q1 2015 | | $0.80 | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Rocket Pharmaceuticals (NASDAQ:RCKT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Rocket Pharmaceuticals (NASDAQ RCKT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 80.91%
Rocket Pharmaceuticals (NASDAQ RCKT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/6/2017 | David P. Southwell | Insider | Buy | 60,000 | $1.75 | $105,000.00 | | |
| 5/13/2016 | J Martin Carroll | Director | Buy | 10,000 | $9.03 | $90,300.00 | 10,000 | |
| 2/23/2015 | Argeris N Karabelas | Director | Buy | 603,832 | $6.00 | $3,622,992.00 | | |
| 2/23/2015 | Park Bioventures Lp Devon | Major Shareholder | Buy | 814,166 | $6.00 | $4,884,996.00 | | |
(Data available from 1/1/2013 forward)
Rocket Pharmaceuticals (NASDAQ RCKT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Rocket Pharmaceuticals (RCKT) Presents At 21st Annual Meeting of the American Society of Gene and Cell Therapy - Slideshow
seekingalpha.com - May 21 at 4:32 PM |
 | Rocket Pharmaceuticals Presents Updated Data from Phase 1/2 Gene Therapy Trial of RP-L102 in Patients with Fanconi Anemia at the American Society of Gene & Cell Therapy (ASGCT ...
www.businesswire.com - May 18 at 4:45 PM |
| Rocket Pharma's lead candidate shows positive effect in Fanconi anemia
seekingalpha.com - May 18 at 4:45 PM |
 | Rocket Pharmaceuticals Presents Updated Data from Phase 1/2 Gene Therapy Trial of RP-L102 in Patients with Fanconi Anemia at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
finance.yahoo.com - May 18 at 4:45 PM |
| Rocket Pharmaceuticals Announces Strategic Research Collaboration
finance.yahoo.com - May 17 at 9:34 AM |
| Rocket Pharmaceuticals Appoints Gayatri R. Rao, MD, JD, Former US Food and Drug Administration Director of the ...
www.businesswire.com - May 16 at 9:33 AM |
| Reader Inquiry: Is There Further Upside Ahead For Rocket Pharmaceuticals?
seekingalpha.com - May 15 at 4:56 PM |
| Rocket Pharmaceuticals Appoints Gayatri R. Rao, M.D., J.D., Former U.S. Food and Drug Administration Director of the Office of Orphan Products Development, as Vice President ...
www.businesswire.com - May 15 at 9:49 AM |
| Rocket Pharmaceuticals Appoints Gayatri R. Rao, M.D., J.D., Former U.S. Food and Drug Administration Director of the Office of Orphan Products Development, as Vice President, Regulatory Policy and Patient Advocacy
finance.yahoo.com - May 15 at 9:49 AM |
 | Rocket Pharmaceuticals (RCKT) Announces Quarterly Earnings Results, Misses Estimates By $0.14 EPS
www.americanbankingnews.com - May 12 at 12:10 PM |
| Rocket Pharmaceuticals (RCKT) Receives Buy Rating from Cowen
www.americanbankingnews.com - May 11 at 7:05 PM |
 | Rocket Pharmaceuticals: 1Q Earnings Snapshot
www.cnbc.com - May 11 at 10:09 AM |
| Rocket Pharmaceuticals (RCKT) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 10 at 12:21 PM |
| Rocket Pharmaceuticals (RCKT) Given a $3.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 20 at 2:25 PM |
| Rocket Pharmaceuticals (RCKT) Downgraded by Canaccord Genuity
www.americanbankingnews.com - April 18 at 9:10 PM |
| Rocket Pharmaceuticals (RCKT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 15 at 8:07 AM |
| Rocket Pharmaceuticals (RCKT) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - April 3 at 10:40 AM |
| We Are Seeing a Dreary Liquidation in the Stock Market
finance.yahoo.com - April 2 at 4:36 PM |
| Rocket Pharmaceuticals Inc (RCKT) Short Interest Update
www.americanbankingnews.com - March 30 at 2:02 AM |
| Rocket Pharmaceuticals (RCKT) Earns Outperform Rating from Analysts at Evercore ISI
www.americanbankingnews.com - March 26 at 3:42 PM |
| Comparing Global Blood Therapeutics (GBT) & Rocket Pharmaceuticals (RCKT)
www.americanbankingnews.com - March 25 at 9:23 AM |
| Rocket Pharmaceuticals Inc (RCKT) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 21 at 11:31 AM |
| Rocket Pharmaceuticals (RCKT) and Its Peers Head to Head Comparison
www.americanbankingnews.com - March 13 at 9:36 AM |
| Head to Head Contrast: Rocket Pharmaceuticals (RCKT) & Its Peers
www.americanbankingnews.com - March 12 at 3:10 AM |
 | Cowen Starts Rocket Pharmaceuticals (RCKT) at Outperform - StreetInsider.com
www.streetinsider.com - March 10 at 5:28 PM |
| Rocket Pharmaceuticals (RCKT) Coverage Initiated at Cowen
www.americanbankingnews.com - March 9 at 4:23 PM |
| Rocket Pharmaceuticals to Present at the Cowen & Company 38 - Business Wire (press release)
www.businesswire.com - March 7 at 9:28 AM |
| Rocket Pharmaceuticals Reports Full Year 2017 Financial Results and Operational Highlights - Business Wire (press release)
www.businesswire.com - March 7 at 9:28 AM |
| Rocket Pharmaceuticals Reports Full Year 2017 Financial Results and Operational Highlights
finance.yahoo.com - March 6 at 9:12 AM |
| Rocket Pharmaceuticals to Present at the Cowen & Company 38th Annual Health Care Conference
finance.yahoo.com - March 5 at 9:31 AM |
| Rocket Pharmaceuticals Inc (RCKT) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 24 at 8:08 AM |
| Intec Pharma (NTEC) vs. Rocket Pharmaceuticals (RCKT) Head to Head Review
www.americanbankingnews.com - February 20 at 11:18 PM |
| Analyzing Rocket Pharmaceuticals (RCKT) and Its Competitors
www.americanbankingnews.com - February 18 at 12:08 PM |
| Analyzing Rocket Pharmaceuticals (RCKT) and Its Rivals
www.americanbankingnews.com - February 14 at 3:14 PM |
| Rocket Pharmaceuticals Announces Participation in a Fireside Chat at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 7 at 9:18 AM |
| Rocket Pharmaceuticals Inc (RCKT) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 30 at 9:40 AM |
| Rocket Pharmaceuticals Inc (RCKT) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 27 at 7:12 PM |
| Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 24 at 9:44 AM |
| Rocket Pharmaceuticals Prices Public Offering of Common Stock
finance.yahoo.com - January 24 at 9:44 AM |
| Critical Comparison: Anthera Pharmaceuticals (ANTH) vs. Rocket Pharmaceuticals (RCKT)
www.americanbankingnews.com - January 21 at 11:10 PM |
 | BRIEF-Tang Capital Partners Reports 8.1 Pct Passive Stake In Rocket Pharmaceuticals - SEC Filing
www.reuters.com - January 17 at 12:05 PM |
| Rocket Pharmaceuticals (RCKT) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - January 9 at 6:26 PM |
Rocket Pharmaceuticals (NASDAQ:RCKT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Rocket Pharmaceuticals (NASDAQ:RCKT) Income Statement, Balance Sheet and Cash Flow Statement
Rocket Pharmaceuticals (NASDAQ RCKT) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
